What is Wedbush’s Estimate for Replimune Group Q3 Earnings?

Replimune Group, Inc. (NASDAQ:REPL) – Analysts at Wedbush boosted their Q3 2025 earnings per share (EPS) estimates for shares of Replimune Group in a research report issued on Tuesday, November 12th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.68) per share for the quarter, up from their previous estimate of ($0.80). The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. Wedbush also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.82) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.89) EPS, Q3 2026 earnings at ($0.61) EPS, Q4 2026 earnings at ($0.61) EPS, FY2026 earnings at ($3.28) EPS, FY2027 earnings at ($2.26) EPS, FY2028 earnings at ($2.08) EPS and FY2029 earnings at ($1.38) EPS.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.07.

Several other brokerages have also recently issued reports on REPL. Roth Capital raised Replimune Group to a “strong-buy” rating in a report on Tuesday, August 27th. Roth Mkm assumed coverage on Replimune Group in a research report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $17.00 target price on shares of Replimune Group in a report on Tuesday, November 12th. Finally, JPMorgan Chase & Co. increased their price target on shares of Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $16.80.

Replimune Group Trading Down 5.3 %

NASDAQ REPL opened at $10.80 on Friday. Replimune Group has a 1 year low of $4.92 and a 1 year high of $12.97. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.11 and a quick ratio of 13.46. The company has a market capitalization of $738.94 million, a PE ratio of -3.54 and a beta of 1.19. The company has a fifty day moving average of $11.46 and a 200 day moving average of $9.57.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC grew its stake in Replimune Group by 10,304.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after acquiring an additional 4,946 shares during the period. Point72 DIFC Ltd acquired a new stake in shares of Replimune Group in the second quarter valued at about $57,000. Erste Asset Management GmbH purchased a new stake in shares of Replimune Group during the third quarter worth about $133,000. Arizona State Retirement System acquired a new position in shares of Replimune Group during the 2nd quarter worth about $108,000. Finally, China Universal Asset Management Co. Ltd. lifted its stake in Replimune Group by 82.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,140 shares of the company’s stock valued at $144,000 after buying an additional 5,926 shares in the last quarter. 92.53% of the stock is owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.